IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Sold by Victory Capital Management Inc.

Victory Capital Management Inc. trimmed its position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 0.9% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 313,257 shares of the company’s stock after selling 2,848 shares during the period. Victory Capital Management Inc. owned 0.37% of IDEAYA Biosciences worth $9,924,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of IDYA. Allworth Financial LP raised its holdings in shares of IDEAYA Biosciences by 800.0% during the third quarter. Allworth Financial LP now owns 900 shares of the company’s stock valued at $29,000 after acquiring an additional 800 shares during the period. Covestor Ltd raised its holdings in shares of IDEAYA Biosciences by 23,050.0% during the third quarter. Covestor Ltd now owns 926 shares of the company’s stock valued at $29,000 after acquiring an additional 922 shares during the period. Quest Partners LLC acquired a new stake in shares of IDEAYA Biosciences during the second quarter valued at approximately $41,000. US Bancorp DE grew its position in IDEAYA Biosciences by 67.2% during the third quarter. US Bancorp DE now owns 1,714 shares of the company’s stock valued at $54,000 after purchasing an additional 689 shares in the last quarter. Finally, Comerica Bank grew its position in IDEAYA Biosciences by 723.5% during the first quarter. Comerica Bank now owns 1,507 shares of the company’s stock valued at $66,000 after purchasing an additional 1,324 shares in the last quarter. 98.29% of the stock is owned by institutional investors and hedge funds.

IDEAYA Biosciences Price Performance

NASDAQ:IDYA opened at $26.60 on Friday. The stock has a market cap of $2.30 billion, a P/E ratio of -11.42 and a beta of 0.86. IDEAYA Biosciences, Inc. has a one year low of $25.20 and a one year high of $47.74. The company has a fifty day moving average price of $30.60 and a 200 day moving average price of $35.94.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its quarterly earnings data on Monday, November 4th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.03. During the same quarter last year, the firm posted ($0.46) earnings per share. As a group, equities research analysts anticipate that IDEAYA Biosciences, Inc. will post -2.46 EPS for the current year.

Analysts Set New Price Targets

IDYA has been the topic of a number of research analyst reports. Leerink Partnrs downgraded shares of IDEAYA Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 5th. Lifesci Capital raised shares of IDEAYA Biosciences to a “strong-buy” rating in a research report on Monday, July 29th. Citigroup decreased their target price on shares of IDEAYA Biosciences from $60.00 to $58.00 and set a “buy” rating for the company in a research report on Tuesday, August 27th. Cantor Fitzgerald initiated coverage on shares of IDEAYA Biosciences in a research report on Tuesday, October 15th. They issued an “overweight” rating for the company. Finally, JPMorgan Chase & Co. decreased their target price on shares of IDEAYA Biosciences from $69.00 to $66.00 and set an “overweight” rating for the company in a research report on Thursday, August 8th. Two equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, IDEAYA Biosciences has a consensus rating of “Moderate Buy” and an average price target of $53.67.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.